Gastroparesis Treatment Market Synopsis:
The Gastroparesis Treatment Market was valued at USD 6.4 billion in 2023 and is predicted to reach USD 9.5 billion by 2032, at a CAGR of 4.5% during the forecast period of 2024-2032.
The gastroparesis treatment market shall be defined as the portion of the healthcare industry devoted to management and treatment of gastroparesis, a disease which is associated with delayed gastric emptying but without any evidence of mechanical obstruction. This condition causes severe complications of the digestive tract, such as nausea, vomiting, swelling and finally poor nutrition. This topic involves numerous products which include drugs to stimulate stomach muscles, changes in diet and other surgeries such as gastric electrical stimulation. Furthermore, the findings of this systemic review provide evidence in relation to management of gastroparesis in order to increase knowledge and practice for improved patient quality of life and minimize potential complications in the long run.
The gastroparesis treatment market has been growing due to the rising incidence of GI disorders – most commonly in diabetic patients, which cause gastroparesis. The increase in the customer base of diabetes and more specifically Type 1 has demanded more ways towards gastroparesis cure. Furthermore, awareness and knowledge of gastrointestinal diseases have improved due to heightened publicity of their symptoms as well as increased modern diagnostic techniques hence early diagnosis and subsequent management of the disease. Some of the new antiemetic segments, prokinetic agents and drugs that treats nausea have opened new opportunities to the firms in the market.
Also, the rise in the healthcare expenditure towards tackling gastroparesis in the emerging nations and ongoing research activities in enhancing gastroparesis management profiles are the factors that fuel the market. They are in the process of creating better value through innovations for example in matters touching on surgical techniques as well as coming up with new formulations that are better for patients. Another advantage has been the increasing trial in clinic trials aimed at new drugs for the treatment of both diabetic and idiopathic gastroparesis thus increasing the options for patients globally.
Gastroparesis Treatment Market Trend Analysis:
Growing Adoption of Prokinetic Agents
- Due to the increasing popularity of gastroparesis among patients, the use of prokinetic agents, which can be considered one of the trends in the market, has grown louder. Such agents include metoclopramide and domperidone that are commonly used to stimulate the muscles of the stomach and promote the movement of the stomach. Over the last few years, prokinetic drugs have undergone a process of “fine-tuning” to decrease adverse effects while increasing efficacy. The run for prokinetic agents has also increased due to their approval and availability in the markets other the Asia Pacific, especially in North America and Europe. Moreover, the combination of prokinetics with other therapeutic regimens such as antiemetic agents has indicated the potential for enhancing patient care management a factor that is expected to foster the growth of the market.
Experiencing a rise in diabetes prevalence
- New entrants in the gastroparesis treatment market find the emerging economies full of growth potential. India, China, and Brazil have indicated increased trends in the number of individuals with diabetes through changes in diets, level of physical activities, and rising obesity levels. The reported increase in the diabetic population which is an essential risk factor for gastroparesis is fueling the elaboration for appropriate treatments for the disease. Moreover, the cost of health care is rising in these areas, the government and private organizations are putting more capital into the enhanced medical framework and treatment regimens. The market which is relatively unsaturated with products accompanied by a recent increase in people’s awareness on the health of their digestive systems means that emerging markets should be strategic focuses of multinational pharmaceutical companies.
Gastroparesis Treatment Market Segment Analysis:
Gastroparesis Treatment Market is Segmented based on type, Drug Class, Treatment, and Region
By Type, Diabetic segment is expected to dominate the market during the forecast period
- The diabetic segment is anticipated to hold the largest market share for gastroparesis treatment in the forecast period due to the fact that diabetes and especially type 2 diabetes is on the rise and has an increased risk for gastroparesis as a complication. Diabetic gastroparesis occurs when diabetic nerve damage affects the muscles of the stomach and small intestine leading to slow gastric emptying. Due to the growing elder population global prevalence of diabetes mellitus has escalated resulting in the need for separate treatment programs as well as prokinetic agents for disorder such as diabetic gastroparesis and antiemetic drugs. Technologically, diabetic care and diagnosis have enhanced the management of gastroparesis pharmaceutical industries invest in the manufacture of a specialized medicines for this segment.
By Drug Class, Prokinetic agents segment expected to held the largest share
- The research report is intended to service the prokinetic agents segment as the largest growth contributor in the gastroparesis treatment market throughout the forecast period. This medication for example the metoclopramide and domperidone is used to improve the contractions of the stomach lining and thus hasten the emptying of food from the stomach. It should be mentioned that prokinetic agents are currently considered to be the most effective method of gastroparesis treatment since they affect the problem place – delayed gastric emptying. Due to constant research to enhance their safety and effectiveness prospects and addition of new and improved prokinetic agents having fewer adverse reactions, the global prokinetic agents segment is expected to retain its dominance in the overall growth projection and increased development in the future years.
Gastroparesis Treatment Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America has been the largest market in the gastroparesis treatment market in 2023. The analysis of the regions` influence can be explained by several factors, such as a high level of diabetes cases, the progression of healthcare, and such significant market participates in the development of the gastroparesis solution. On the same note, the United States is outstanding in diagnosing and treating the condition, which has attributed to the large share in the regional market. Currently, the North American region captured about 45 percent of global market share in 2023. It is backed up by large investment in research and development, especially in new drugs and devices to better treat the symptoms of gastroparesis.
Active Key Players in the Gastroparesis Treatment Market
- Abbott Laboratories (USA)
- Allergan (Ireland)
- AstraZeneca plc (UK)
- Boston Scientific Corporation (USA)
- Cipla Ltd. (India)
- Evoke Pharma (USA)
- GlaxoSmithKline plc (UK)
- Ironwood Pharmaceuticals (USA)
- Johnson & Johnson (USA)
- Medtronic (USA)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Takeda Pharmaceutical Company (Japan)
- Teva Pharmaceuticals (Israel)
- Thera Vance Biopharma (USA)
- Other Active Players
Key Industry Developments in the Gastroparesis Treatment Market:
- In December 2022, A United States Patent No. 11,517,545 under the title "Treatment of Moderate and Severe Gastroparesis" has been issued by the United States Patent and Trademark Office (USPTO), according to a statement made by Evoke Pharma, Inc., utilizing GIMOTI.
- In April 2022, in a Phase 2A clinical trial with PCS12852, Processa Pharmaceuticals, Inc. recruited its first patient, a patient with moderate-to-severe gastroparesis.
|
Global Gastroparesis Treatment Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 6.4 Billion |
|
Forecast Period 2024-32 CAGR: |
4.5% |
Market Size in 2032: |
USD 9.5 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Drug Class |
|
||
|
By Treatment |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Gastroparesis Treatment Market by By Type (2018-2032)
4.1 Gastroparesis Treatment Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Idiopathic
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Diabetic
4.5 Post- Surgical
Chapter 5: Gastroparesis Treatment Market by By Drug Class (2018-2032)
5.1 Gastroparesis Treatment Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Prokinetic agents
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Antiemetic drugs
5.5 Proton pump inhibitors
Chapter 6: Gastroparesis Treatment Market by By Treatment (2018-2032)
6.1 Gastroparesis Treatment Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Jejunostomy
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Gastric Electric Stimulation
6.5 Parenteral Nutrition
6.6 Diabetic Gastroparesis
6.7 Chronic Gastroparesis
6.8 Idiopathic Gastroparesis
6.9 Post-Operative Gastroparesis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Gastroparesis Treatment Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBOTT LABORATORIES (USA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ALLERGAN (IRELAND)
7.4 ASTRAZENECA PLC (UK)
7.5 BOSTON SCIENTIFIC CORPORATION (USA)
7.6 CIPLA LTD. (INDIA)
7.7 EVOKE PHARMA (USA)
7.8 GLAXOSMITHKLINE PLC (UK)
7.9 IRONWOOD PHARMACEUTICALS (USA)
7.10 JOHNSON & JOHNSON (USA)
7.11 MEDTRONIC (USA)
7.12 NOVARTIS AG (SWITZERLAND)
7.13 PFIZER INC. (USA)
7.14 TAKEDA PHARMACEUTICAL COMPANY (JAPAN)
7.15 TEVA PHARMACEUTICALS (ISRAEL)
7.16 THERA VANCE BIOPHARMA (USA)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Gastroparesis Treatment Market By Region
8.1 Overview
8.2. North America Gastroparesis Treatment Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By By Type
8.2.4.1 Idiopathic
8.2.4.2 Diabetic
8.2.4.3 Post- Surgical
8.2.5 Historic and Forecasted Market Size By By Drug Class
8.2.5.1 Prokinetic agents
8.2.5.2 Antiemetic drugs
8.2.5.3 Proton pump inhibitors
8.2.6 Historic and Forecasted Market Size By By Treatment
8.2.6.1 Jejunostomy
8.2.6.2 Gastric Electric Stimulation
8.2.6.3 Parenteral Nutrition
8.2.6.4 Diabetic Gastroparesis
8.2.6.5 Chronic Gastroparesis
8.2.6.6 Idiopathic Gastroparesis
8.2.6.7 Post-Operative Gastroparesis
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Gastroparesis Treatment Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By By Type
8.3.4.1 Idiopathic
8.3.4.2 Diabetic
8.3.4.3 Post- Surgical
8.3.5 Historic and Forecasted Market Size By By Drug Class
8.3.5.1 Prokinetic agents
8.3.5.2 Antiemetic drugs
8.3.5.3 Proton pump inhibitors
8.3.6 Historic and Forecasted Market Size By By Treatment
8.3.6.1 Jejunostomy
8.3.6.2 Gastric Electric Stimulation
8.3.6.3 Parenteral Nutrition
8.3.6.4 Diabetic Gastroparesis
8.3.6.5 Chronic Gastroparesis
8.3.6.6 Idiopathic Gastroparesis
8.3.6.7 Post-Operative Gastroparesis
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Gastroparesis Treatment Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By By Type
8.4.4.1 Idiopathic
8.4.4.2 Diabetic
8.4.4.3 Post- Surgical
8.4.5 Historic and Forecasted Market Size By By Drug Class
8.4.5.1 Prokinetic agents
8.4.5.2 Antiemetic drugs
8.4.5.3 Proton pump inhibitors
8.4.6 Historic and Forecasted Market Size By By Treatment
8.4.6.1 Jejunostomy
8.4.6.2 Gastric Electric Stimulation
8.4.6.3 Parenteral Nutrition
8.4.6.4 Diabetic Gastroparesis
8.4.6.5 Chronic Gastroparesis
8.4.6.6 Idiopathic Gastroparesis
8.4.6.7 Post-Operative Gastroparesis
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Gastroparesis Treatment Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By By Type
8.5.4.1 Idiopathic
8.5.4.2 Diabetic
8.5.4.3 Post- Surgical
8.5.5 Historic and Forecasted Market Size By By Drug Class
8.5.5.1 Prokinetic agents
8.5.5.2 Antiemetic drugs
8.5.5.3 Proton pump inhibitors
8.5.6 Historic and Forecasted Market Size By By Treatment
8.5.6.1 Jejunostomy
8.5.6.2 Gastric Electric Stimulation
8.5.6.3 Parenteral Nutrition
8.5.6.4 Diabetic Gastroparesis
8.5.6.5 Chronic Gastroparesis
8.5.6.6 Idiopathic Gastroparesis
8.5.6.7 Post-Operative Gastroparesis
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Gastroparesis Treatment Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By By Type
8.6.4.1 Idiopathic
8.6.4.2 Diabetic
8.6.4.3 Post- Surgical
8.6.5 Historic and Forecasted Market Size By By Drug Class
8.6.5.1 Prokinetic agents
8.6.5.2 Antiemetic drugs
8.6.5.3 Proton pump inhibitors
8.6.6 Historic and Forecasted Market Size By By Treatment
8.6.6.1 Jejunostomy
8.6.6.2 Gastric Electric Stimulation
8.6.6.3 Parenteral Nutrition
8.6.6.4 Diabetic Gastroparesis
8.6.6.5 Chronic Gastroparesis
8.6.6.6 Idiopathic Gastroparesis
8.6.6.7 Post-Operative Gastroparesis
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Gastroparesis Treatment Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By By Type
8.7.4.1 Idiopathic
8.7.4.2 Diabetic
8.7.4.3 Post- Surgical
8.7.5 Historic and Forecasted Market Size By By Drug Class
8.7.5.1 Prokinetic agents
8.7.5.2 Antiemetic drugs
8.7.5.3 Proton pump inhibitors
8.7.6 Historic and Forecasted Market Size By By Treatment
8.7.6.1 Jejunostomy
8.7.6.2 Gastric Electric Stimulation
8.7.6.3 Parenteral Nutrition
8.7.6.4 Diabetic Gastroparesis
8.7.6.5 Chronic Gastroparesis
8.7.6.6 Idiopathic Gastroparesis
8.7.6.7 Post-Operative Gastroparesis
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Global Gastroparesis Treatment Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 6.4 Billion |
|
Forecast Period 2024-32 CAGR: |
4.5% |
Market Size in 2032: |
USD 9.5 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Drug Class |
|
||
|
By Treatment |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Global Gastroparesis Treatment Market research report is 2024-2032.
Abbott Laboratories (USA), Allergan (Ireland), AstraZeneca plc (UK), Boston Scientific Corporation (USA), Cipla Ltd. (India), Evoke Pharma (USA), GlaxoSmithKline plc (UK), Ironwood Pharmaceuticals (USA), Johnson & Johnson (USA), Medtronic (USA), Novartis AG (Switzerland), Pfizer Inc. (USA), Takeda Pharmaceutical Company (Japan), Teva Pharmaceuticals (Israel), Thera Vance Biopharma (USA), and Other Active Players.
The Gastroparesis Treatment Market is segmented into Type, Drug Class, Treatment and region. By Type, the market is categorized into Idiopathic, Diabetic, Post- Surgical and Others. By Drug Class, the market is categorized into Prokinetic agents, Antiemetic drugs, Proton pump inhibitors. By Treatment, the market is categorized into Jejunostomy, Gastric Electric Stimulation, Parenteral Nutrition, Diabetic Gastroparesis, Chronic Gastroparesis, Idiopathic Gastroparesis and Post-Operative Gastroparesis. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
The gastroparesis treatment market shall be defined as the portion of the healthcare industry devoted to management and treatment of gastroparesis, a disease which is associated with delayed gastric emptying but without any evidence of mechanical obstruction. This condition causes severe complications of the digestive tract, such as nausea, vomiting, swelling and finally poor nutrition. This topic involves numerous products which include drugs to stimulate stomach muscles, changes in diet and other surgeries such as gastric electrical stimulation. Furthermore, the findings of this systemic review provide evidence in relation to management of gastroparesis in order to increase knowledge and practice for improved patient quality of life and minimize potential complications in the long run.
Gastroparesis Treatment Market Size Was Valued at USD 6.4 Billion in 2023, and is Projected to Reach USD 9.5 Billion by 2032, Growing at a CAGR of 4.5% From 2024-2032.
